Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria

Chandy John, Elizabeth Kutamba, Keith Mugarura, Robert O. Opoka

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Severe malaria due to Plasmodium falciparum causes more than 800,000 deaths every year. Primary therapy with quinine or artesunate is generally effective in controlling P. falciparum parasitemia, but mortality from cerebral malaria and other forms of severe malaria remains unacceptably high. Long-term cognitive impairment is also common in children with cerebral malaria. Of the numerous adjunctive therapies for cerebral malaria and severe malaria studied over the past five decades, only one (albumin) was associated with a reduction in mortality. In this article, we review past and ongoing studies of adjunctive therapy, and examine the evidence of efficacy for newer therapies, including inhibitors of cytoadherence (e.g., levamisole), immune modulators (e.g., rosiglitazone), agents that increase nitric oxide levels (e.g., arginine) and neuroprotective agents (e.g., erythropoietin).

Original languageEnglish (US)
Pages (from-to)997-1008
Number of pages12
JournalExpert Review of Anti-Infective Therapy
Volume8
Issue number9
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Cerebral Malaria
Falciparum Malaria
Malaria
rosiglitazone
Plasmodium falciparum
Levamisole
Quinine
Parasitemia
Mortality
Neuroprotective Agents
Therapeutics
Erythropoietin
Arginine
Albumins
Nitric Oxide

Keywords

  • adjunctive
  • cerebral
  • human
  • malaria
  • Plasmodium falciparum
  • severe
  • treatment

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology

Cite this

Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria. / John, Chandy; Kutamba, Elizabeth; Mugarura, Keith; Opoka, Robert O.

In: Expert Review of Anti-Infective Therapy, Vol. 8, No. 9, 09.2010, p. 997-1008.

Research output: Contribution to journalArticle

John, Chandy ; Kutamba, Elizabeth ; Mugarura, Keith ; Opoka, Robert O. / Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria. In: Expert Review of Anti-Infective Therapy. 2010 ; Vol. 8, No. 9. pp. 997-1008.
@article{9881fbd8c3d94c0a8a40822e61583cdd,
title = "Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria",
abstract = "Severe malaria due to Plasmodium falciparum causes more than 800,000 deaths every year. Primary therapy with quinine or artesunate is generally effective in controlling P. falciparum parasitemia, but mortality from cerebral malaria and other forms of severe malaria remains unacceptably high. Long-term cognitive impairment is also common in children with cerebral malaria. Of the numerous adjunctive therapies for cerebral malaria and severe malaria studied over the past five decades, only one (albumin) was associated with a reduction in mortality. In this article, we review past and ongoing studies of adjunctive therapy, and examine the evidence of efficacy for newer therapies, including inhibitors of cytoadherence (e.g., levamisole), immune modulators (e.g., rosiglitazone), agents that increase nitric oxide levels (e.g., arginine) and neuroprotective agents (e.g., erythropoietin).",
keywords = "adjunctive, cerebral, human, malaria, Plasmodium falciparum, severe, treatment",
author = "Chandy John and Elizabeth Kutamba and Keith Mugarura and Opoka, {Robert O.}",
year = "2010",
month = "9",
doi = "10.1586/eri.10.90",
language = "English (US)",
volume = "8",
pages = "997--1008",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria

AU - John, Chandy

AU - Kutamba, Elizabeth

AU - Mugarura, Keith

AU - Opoka, Robert O.

PY - 2010/9

Y1 - 2010/9

N2 - Severe malaria due to Plasmodium falciparum causes more than 800,000 deaths every year. Primary therapy with quinine or artesunate is generally effective in controlling P. falciparum parasitemia, but mortality from cerebral malaria and other forms of severe malaria remains unacceptably high. Long-term cognitive impairment is also common in children with cerebral malaria. Of the numerous adjunctive therapies for cerebral malaria and severe malaria studied over the past five decades, only one (albumin) was associated with a reduction in mortality. In this article, we review past and ongoing studies of adjunctive therapy, and examine the evidence of efficacy for newer therapies, including inhibitors of cytoadherence (e.g., levamisole), immune modulators (e.g., rosiglitazone), agents that increase nitric oxide levels (e.g., arginine) and neuroprotective agents (e.g., erythropoietin).

AB - Severe malaria due to Plasmodium falciparum causes more than 800,000 deaths every year. Primary therapy with quinine or artesunate is generally effective in controlling P. falciparum parasitemia, but mortality from cerebral malaria and other forms of severe malaria remains unacceptably high. Long-term cognitive impairment is also common in children with cerebral malaria. Of the numerous adjunctive therapies for cerebral malaria and severe malaria studied over the past five decades, only one (albumin) was associated with a reduction in mortality. In this article, we review past and ongoing studies of adjunctive therapy, and examine the evidence of efficacy for newer therapies, including inhibitors of cytoadherence (e.g., levamisole), immune modulators (e.g., rosiglitazone), agents that increase nitric oxide levels (e.g., arginine) and neuroprotective agents (e.g., erythropoietin).

KW - adjunctive

KW - cerebral

KW - human

KW - malaria

KW - Plasmodium falciparum

KW - severe

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=77956484683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956484683&partnerID=8YFLogxK

U2 - 10.1586/eri.10.90

DO - 10.1586/eri.10.90

M3 - Article

C2 - 20818944

AN - SCOPUS:77956484683

VL - 8

SP - 997

EP - 1008

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 9

ER -